Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Prevnar 13

- PMLiVE

Novartis raises pressure in Pfizer’s Ibrance with new Kisqali data

Women on Kisqali were found to have a longer PFS than those on hormonal therapy alone

Pharma’s digital patient engagement innovators identified

Novartis, Pfizer and Sanofi named best-in-class by Decision Resources Group

- PMLiVE

CDC backs GSK’s Shingrix over Merck & Co’s Zostavax

US advisors recommend GSK's shingle vaccine be used instead of Merck's rival product

AstraZeneca AZ

AZ and MSD win FDA priority review for Lynparza in breast cancer

Could become the first PARP inhibitor to be approved in the US for the disease

- PMLiVE

CHMP recommends Teva’s generic version of Astellas’ Advagraf

Committee backs the drug for transplant rejection prophylaxis

- PMLiVE

CETP inhibitor class finally dies as Merck abandons anacetrapib

Cholesterol drug fails to “support regulatory filings”

- PMLiVE

NICE backs Pfizer’s Xeljanz for RA

But UK’s cost-effectiveness watchdog removes two drugs from CDF

- PMLiVE

Pfizer could raise ‘up to $15bn’ from consumer unit sale

Would follow in the footsteps of Novartis, Boehringer and Merck & Co if it does strike a deal

- PMLiVE

Merck & Co pulls out of hepatitis C R&D as market shrinks

Discontinues its new-generation treatments but Zepatier is still making headway

- PMLiVE

Keytruda adds stomach cancer to growing list of US approvals

FDA clears the drug as a third-line option after chemotherapy

- PMLiVE

Pfizer spins out SpringWorks Therapeutics biotech

Former Pfizer VP Lara Sullivan takes the helm at the newly-formed company

- PMLiVE

Merck, Pfizer cue up first EU launches for PD-L1 drug Bavencio

Germany and the UK will be the first to receive the skin cancer treatment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links